Lymphovascular invasion as a tool to further subclassify T1b esophageal adenocarcinoma (pages 1020–1027)
Putao Cen, Wayne L. Hofstetter, Arlene M. Correa, Tsung-Teh Wu, Jeffery H. Lee, William A. Ross, Marta Davilla, Stephen G. Swisher, Norio Fukami, Asif Rashid, Dipen Maru and Jaffer A. Ajani
Version of Record online: 18 JAN 2008 | DOI: 10.1002/cncr.23265
Although endoscopic therapy may be adequate for patients with T1a esophageal adenocarcinoma, patients with T1b disease require esophagectomy/lymphadenectomy. In this study, the authors hypothesized that lymphovascular invasion (LVI) status would subclassify T1b cancers and facilitate new therapeutic strategies. The results demonstrated that LVI distinguishes the biologic behavior of early esophageal cancer, and patients who have T1b esophageal adenocarcinoma without LVI have a clinical biology similar to that of patients who have T1a tumors.